MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
VistaGen Therapeutics Total Non Current Liabilities 2011-2026 | VTGN
Annual Total Non Current Liabilities VistaGen Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 4.16 M | 12.1 M | 8.73 M | 4.14 M | 2.9 M | 1.73 M | 2.17 M | 3.42 M | 7.86 M | 11 M | 2.87 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.1 M | 1.73 M | 5.56 M |
Quarterly Total Non Current Liabilities VistaGen Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 3.64 M | 4.13 M | 4.44 M | 4.75 M | 5.05 M | 3.75 M | 4.16 M | 4.14 M | 11.9 M | 12 M | 12.1 M | 12.5 M | 12.7 M | 9.11 M | 8.73 M | 8.49 M | 8.25 M | 8.01 M | 4.14 M | 3.86 M | 3.59 M | 3.16 M | 2.9 M | 2.65 M | 2.4 M | 2.04 M | 1.73 M | 1.42 M | 1.14 M | 994 K | 2.17 M | 1.51 M | 909 K | 1.33 M | 3.42 M | 7.28 M | 10.9 M | 9.96 M | 7.86 M | 8.29 M | 9.91 M | 9.45 M | 7.86 M | 8.27 M | 3.94 M | 2.54 M | 11 M | 2.94 M | 3.07 M | 3.21 M | 7.85 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 M | 909 K | 5.72 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Ultragenyx Pharmaceutical
RARE
|
416 M | $ 19.23 | -3.85 % | $ 1.9 B |  USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
3.48 M | $ 0.8 | 0.89 % | $ 428 M |  Israel |
 |
Dr. Reddy's Laboratories Limited
RDY
|
9.04 B | $ 13.56 | -1.56 % | $ 2.25 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
1.62 B | $ 742.02 | -1.94 % | $ 77.6 B | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Replimune Group
REPL
|
38.5 M | $ 7.22 | -4.24 % | $ 582 M | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
REGENXBIO
RGNX
|
14 M | $ 7.88 | -4.6 % | $ 406 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | USA |
 |
Rigel Pharmaceuticals
RIGL
|
35.5 M | $ 26.2 | -0.64 % | $ 471 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Avidity Biosciences
RNA
|
152 M | $ 13.09 | -0.08 % | $ 1.8 B | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
3.09 M | $ 78.52 | -4.13 % | $ 5.1 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 12.57 | -9.96 % | $ 1.91 B | USA |
 |
Sana Biotechnology
SANA
|
538 M | $ 2.78 | -8.42 % | $ 704 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
SIGA Technologies
SIGA
|
9.05 M | $ 5.35 | 7.76 % | $ 383 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 321.71 | -1.96 % | $ 42.1 B | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | USA |
 |
Silence Therapeutics plc
SLN
|
51.3 M | $ 4.8 | -9.6 % | $ 622 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
299 K | $ 1.08 | -0.92 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
425 K | - | - | $ 40.5 M | USA |